- Clene Inc CLNN announced new results shows obtained ALS Patient Function Score (ALSFRS-R) and Delayed Time to Clinical Worsening from the most recent 12-month data cut-off of the open-label extension (OLE) of the Phase 2 RESCUE ALS study in people with early amyotrophic lateral sclerosis ( ALS) treated with CNM-Au8.
- CNM-Au8 preserved physical function when administered for 48 weeks as measured by the ALSFRS-R, a clinical assessment measuring activities such as walking, speaking, breathing, feeding and independent dressing.
- Related: Clene shares rise on encouraging data from multiple sclerosis candidates.
- Significant functional survival (ALSFRS-R) was observed from randomization to 48 weeks, with significant functional survival during the open-label long-term extension week (OLE) from 24 to 120 weeks after randomization.
- Significantly reduced risk of clinical worsening of ALS by 52% over 120 weeks.
- CNM-Au8 treatment was well tolerated with no long-term safety concerns.
- Price promotion: CLNN shares are up 4.17% to $1.25 on Monday’s latest check.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
[ad_2]
Source story
